Sorry, but no relevant information or results could be found for your search.
thenextweb
Akeso’s lung cancer drug reduces death risk by 34%, marking the first Chinese drug at ASCO’s top stage in 61 years
Akeso, the Chinese biotechnology company whose drug ivonescimab was dubbed “biotech’s DeepSeek moment” last year, has reported phase three clinical trial results showing a 34% reduction in the risk of death for patients with advanced squamous non-small cell lung cancer. The data, filed with the Hong Kong stock exchange on Monday and selected for the American Society […]<br /> This [...]
